ARIUS Announces Third Quarter Fiscal 2007 Financi...(he increaseswere primarily the result of...)

Date:10/12/2007

he increases were primarily the result of increased product development activity, including process development and scale-up, as the Company prepares several of its programs for the clinic as well as an increase in staffing levels and stock option remuneration expense.

General and administrative expenses increased to $2,833,070 for the nine-month period ended August 31, 2007, compared to $2,162,020 for the same period in fiscal 2006. For the three-month period ended August 31, 2007, the Company's general and administrative expenses increased to $1,160,827 compared to $470,619 for the same period in fiscal 2006. The increases were primarily the result of increased head count, stock option remuneration, and severance costs, partially offset by decreased consulting and legal costs.

As at August 31, 2007, the Company's cash and cash equivalents, short-term investments and working capital position were $6,201,996, $7,962,663 and $12,035,539 respectively, compared with November 30, 2006 balances of $4,077,065, $16,135,490 and $20,263,807, respectively. The Company believes that it has adequate financial resources for anticipated expenditures until the fourth quarter of fiscal 2008.

As at October 10, 2007, the Company had: 44,750,964 Common Shares outstanding; 34,953,526 Warrants; 2,121,808 Compensation Warrants; and 4,019,705 Stock Options.

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 400 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For
'/>"/>

SOURCE ARIUS Research Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related biology technology :

1. Streptococcus salivarius
2. Streptococcus salivarius
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition